Integrative Physiology |
From the Medizinische Klinik und Poliklinik (S.W., M.S., K.S., M.B., G.N.), Innere Medizin III, and Physiologisches Institut (A.S.), Universitätskliniken des Saarlandes, Homburg/Saar, Germany; and Department of Cardiology and Angiology (B.S.), Medizinische Hochschule Hannover, Hannover, Germany.
Correspondence to Dr Sven Wassmann, Medizinische Klinik und Poliklinik, Innere Medizin III, Universitätskliniken des Saarlandes, D-66421 Homburg/Saar, Germany. E-mail wassmann{at}med-in.uni-saarland.de
Angiotensin II type 1 (AT1) receptor activation as well as proinflammatory cytokines such as interleukin-6 (IL-6) are involved in the development and progression of atherosclerosis. The detailed underlying mechanisms including interactions between inflammatory agonists and the renin-angiotensin system are poorly understood. Stimulation of cultured rat aortic vascular smooth muscle cells (VSMCs) with IL-6 led to upregulation of AT1 receptor mRNA and protein expression, as assessed by Northern and Western blot experiments. Nuclear run-on and transcription blockade experiments showed that IL-6 increases AT1 receptor mRNA de novo synthesis but not mRNA stability. Preincubation of VSMCs with IL-6 resulted in an enhanced angiotensin IIinduced production of reactive oxygen species, as assessed by DCF fluorescence laser microscopy. Treatment of C57BL/6J mice with IL-6 for 18 days increased vascular AT1 receptor expression (real-time RT-PCR) and angiotensin IIinduced vasoconstriction, enhanced vascular superoxide production (L-012 chemiluminescence, DHE fluorescence), and impaired endothelium-dependent vasodilatation. These effects were completely omitted in AT1 receptor knockout mice (AT1A-/- mice). Upregulation of vascular AT1 receptor expression in vitro and in vivo is decisively involved in IL-6induced propagation of oxidative stress and endothelial dysfunction. This interaction of the proinflammatory cytokine IL-6 with the renin-angiotensin system may represent an important pathogenetic mechanism in the atherosclerotic process.
Key Words: endothelial dysfunction AT1 receptor interleukin-6 inflammation oxidative stress
This article has been cited by other articles:
![]() |
C.-F. Lam, P.-J. Chang, Y.-S. Huang, Y.-H. Sung, C.-C. Huang, M.-W. Lin, Y.-C. Liu, and Y.-C. Tsai Prolonged Use of High-Dose Morphine Impairs Angiogenesis and Mobilization of Endothelial Progenitor Cells in Mice Anesth. Analg., August 1, 2008; 107(2): 686 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Satou, R. A. Gonzalez-Villalobos, K. Miyata, N. Ohashi, A. Katsurada, L. G. Navar, and H. Kobori Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells Am J Physiol Renal Physiol, July 1, 2008; 295(1): F283 - F289. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Martinez-Revelles, F. Jimenez-Altayo, L. Caracuel, F. J. Perez-Asensio, A. M. Planas, and E. Vila Endothelial Dysfunction in Rat Mesenteric Resistance Artery after Transient Middle Cerebral Artery Occlusion J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 363 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chrissobolis, S. P. Didion, D. A. Kinzenbaw, L. I. Schrader, S. Dayal, S. R. Lentz, and F. M. Faraci Glutathione Peroxidase-1 Plays a Major Role in Protecting Against Angiotensin II-Induced Vascular Dysfunction Hypertension, April 1, 2008; 51(4): 872 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. I. Schrader, D. A. Kinzenbaw, A. W. Johnson, F. M. Faraci, and S. P. Didion IL-6 Deficiency Protects Against Angiotensin II Induced Endothelial Dysfunction and Hypertrophy Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2576 - 2581. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Muller, N. Schweitzer, O. Johren, P. Dominiak, and W. Raasch Angiotensin II stimulates the reactivity of the pituitary-adrenal axis in leptin-resistant Zucker rats, thereby influencing the glucose utilization Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E802 - E810. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. I. Boesen and D. M. Pollock Effect of chronic IL-6 infusion on acute pressor responses to vasoconstrictors in mice Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1745 - H1749. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Haurani and P. J. Pagano Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: Bellwether for vascular disease? Cardiovasc Res, September 1, 2007; 75(4): 679 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Zemse, R. H. P. Hilgers, and R. C. Webb Interleukin-10 counteracts impaired endothelium-dependent relaxation induced by ANG II in murine aortic rings Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3103 - H3108. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Wahba and R. H. Mak Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 550 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Elton and M. M. Martin Angiotensin II Type 1 Receptor Gene Regulation: Transcriptional and Posttranscriptional Mechanisms Hypertension, May 1, 2007; 49(5): 953 - 961. [Full Text] [PDF] |
||||
![]() |
T. Kurihara, Y. Ozawa, K. Shinoda, N. Nagai, M. Inoue, Y. Oike, K. Tsubota, S. Ishida, and H. Okano Neuroprotective Effects of Angiotensin II Type 1 Receptor (AT1R) Blocker, Telmisartan, via Modulating AT1R and AT2R Signaling in Retinal Inflammation Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5545 - 5552. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wassmann, N. Werner, T. Czech, and G. Nickenig Improvement of Endothelial Function by Systemic Transfusion of Vascular Progenitor Cells Circ. Res., October 13, 2006; 99(8): E74 - E83. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cheng, W. Cao, J. Behar, C. Fiocchi, P. Biancani, and K. M. Harnett Acid-Induced Release of Platelet-Activating Factor by Human Esophageal Mucosa Induces Inflammatory Mediators in Circular Smooth Muscle J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 117 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cheng, W. Cao, C. Fiocchi, J. Behar, P. Biancani, and K. M. Harnett HCl-induced inflammatory mediators in cat esophageal mucosa and inflammatory mediators in esophageal circular muscle in an in vitro model of esophagitis Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1307 - G1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Lee, L. C. Sturgis, H. Labazi, J. B. Osborne Jr., C. Fleming, J. S. Pollock, M. Manhiani, J. D. Imig, and M. W. Brands Angiotensin II hypertension is attenuated in interleukin-6 knockout mice Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H935 - H940. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Matsuno, H. Yamada, K. Iwata, D. Jin, M. Katsuyama, M. Matsuki, S. Takai, K. Yamanishi, M. Miyazaki, H. Matsubara, et al. Nox1 Is Involved in Angiotensin II-Mediated Hypertension: A Study in Nox1-Deficient Mice Circulation, October 25, 2005; 112(17): 2677 - 2685. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cheng, W. Cao, C. Fiocchi, J. Behar, P. Biancani, and K. M. Harnett Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G418 - G428. [Abstract] [Full Text] [PDF] |
||||
![]() |
I.-S. Song, S. Tatebe, W. Dai, and M. T. Kuo Delayed Mechanism for Induction of {gamma}-Glutamylcysteine Synthetase Heavy Subunit mRNA Stability by Oxidative Stress Involving p38 Mitogen-activated Protein Kinase Signaling J. Biol. Chem., August 5, 2005; 280(31): 28230 - 28240. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Szotowski, S. Antoniak, W. Poller, H.-P. Schultheiss, and U. Rauch Procoagulant Soluble Tissue Factor Is Released From Endothelial Cells in Response to Inflammatory Cytokines Circ. Res., June 24, 2005; 96(12): 1233 - 1239. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Takeda, E. Suzuki, H. Satonaka, S. Oba, H. Nishimatsu, M. Omata, T. Fujita, R. Nagai, and Y. Hirata Blockade of Endogenous Cytokines Mitigates Neointimal Formation in Obese Zucker Rats Circulation, March 22, 2005; 111(11): 1398 - 1406. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Petnehazy, K. Y. Stokes, J. M. Russell, and D. N. Granger Angiotensin II Type-1 Receptor Antagonism Attenuates the Inflammatory and Thrombogenic Responses to Hypercholesterolemia in Venules Hypertension, February 1, 2005; 45(2): 209 - 215. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Bongartz, M. J. Cramer, P. A. Doevendans, J. A. Joles, and B. Braam The severe cardiorenal syndrome: 'Guyton revisited' Eur. Heart J., January 1, 2005; 26(1): 11 - 17. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Wisse The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2792 - 2800. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Williams, J. S. Pollock, and D. M. Pollock Arterial Pressure Response to the Antioxidant Tempol and ETB Receptor Blockade in Rats on a High-Salt Diet Hypertension, November 1, 2004; 44(5): 770 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Nickenig Should Angiotensin II Receptor Blockers and Statins Be Combined? Circulation, August 24, 2004; 110(8): 1013 - 1020. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |